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Prostate-specific membrane antigen (PSMA) is highly expressed in
prostate cancer cells and nonprostatic solid tumor neovasculature
and is a target for anticancer imaging and therapeutic agents.
PSMA acts as a glutamate carboxypeptidase (GCPII) on small
molecule substrates, including folate, the anticancer drug metho-
trexate, and the neuropeptide N-acetyl-L-aspartyl-L-glutamate.
Here we present the 3.5-Å crystal structure of the PSMA ectodo-
main, which reveals a homodimer with structural similarity to
transferrin receptor, a receptor for iron-loaded transferrin that
lacks protease activity. Unlike transferrin receptor, the protease
domain of PSMA contains a binuclear zinc site, catalytic residues,
and a proposed substrate-binding arginine patch. Elucidation of
the PSMA structure combined with docking studies and a proposed
catalytic mechanism provides insight into the recognition of inhib-
itors and the natural substrateN-acetyl-L-aspartyl-L-glutamate. The
PSMA structure will facilitate development of chemotherapeutics,
cancer-imaging agents, and agents for treatment of neurological
disorders.
crystallography  folate hydrolase  glutamate carboxypeptidase II 
Naaladase I
Prostate-specific membrane antigen (PSMA), also known asglutamate carboxypeptidase II (EC 3.4.17.21), N-acetyl--
linked acidic dipeptidase I [Naaladase (NLD) I], or folate
hydrolase, is a 750-residue type II transmembrane glycoprotein
that is highly expressed in prostate cancer cells and in nonpros-
tatic solid tumor neovasculature (1) and expressed at lower levels
in other tissues (2, 3), including healthy prostate, kidney, liver,
small intestine, and brain (reviewed in refs. 4 and 5). PSMA
expression increases with prostate disease progression and me-
tastasis (6), thus PSMA is the target of a Food and Drug
Administration-approved prostate cancer-imaging agent, the
111In-labeled 7E11 monoclonal antibody (Prostascint, Cytogen,
Princeton, NJ), which binds an intracellular epitope exposed
upon cell death. The extracellular domain of PSMA is targeted
by monoclonal antibodies such as J591, which is in clinical trials
for specific delivery of imaging agents or therapeutics to cells
overexpressing PSMA (7).
In addition to its role as a tumor marker, PSMA contains a
binuclear zinc site and is active as a glutamate carboxypeptidase,
catalyzing the hydrolytic cleavage of - or -linked glutamates
from peptides or small molecules (8). Its substrates include
poly--glutamated folates, which are essential nutrients, and the
poly--glutamated form of the anticancer drug methotrexate
(Fig. 1A) (9), in which case cleavage renders it less efficacious.
The enzymatic activity of PSMA can be exploited for the design
of prodrugs, in which an inactive glutamated form of the drug is
selectively cleaved and thereby activated only at cells that express
PSMA (10).
PSMA also cleaves and inactivates the abundant neuropeptide
N-acetyl-L-aspartyl-L-glutamate (-NAAG) (11) (Fig. 1A),
which is an inhibitor of the NMDA ionotropic receptor and an
agonist of the type II metabotropic glutamate receptor subtype
3 (12). A breakdown of the regulation of glutamatergic neuro-
transmission by -NAAG is implicated in schizophrenia, seizure
disorders, Alzheimer’s disease, Huntington’s disease, and amyo-
trophic lateral sclerosis (13). Thus, inhibition of PSMA poten-
tially confers neuroprotection both by reducing glutamate and
increasing -NAAG. Indeed, the subnanomolar inhibitor
2-(phosphonomethyl) pentanedioc acid has been shown to pro-
vide neuroprotection in cell culture andor animal models of
ischemia, diabetic neuropathy, drug abuse, chronic pain, and
amyotrophic lateral sclerosis (14).
PSMA is a member of a superfamily of zinc-dependent
exopeptidases, which include carboxypeptidases with a mono-
nuclear zinc active site (e.g., carboxypeptidase A) (15) and
carboxy- and aminopeptidases with a binuclear zinc active site
[e.g., carboxypeptidase G2 (CPG2) (16), peptidases T and V
(PepT and PepV) (17, 18), Streptomyces griseus aminopeptidase
(Sgap) (19), and Aeromonas proteolytica aminopeptidase (AAP)
(20)]. In addition to a limited region of homology with these
soluble single-domain (e.g., AAP, Fig. 1C) (19, 20) or double-
domain (e.g., CPG2, Fig. 1D) (16–18) zinc-dependent exopep-
tidases, the entire sequence of PSMA is homologous to at least
four other human proteins: NLDL (expressed in ileum; 35%
identity) (2, 21), NLD2 (expressed in ovary, testis, and brain;
67% identity) (2, 21, 22), transferrin receptor (TfR) 1 (TfR1;
expressed in most cell types; 26% identity) (23) (Fig. 1B), and
TfR2 (expressed predominantly in liver; 28% identity) (24). Of
these homologs, only the 3D structure of TfR1 is available; it is
a type II transmembrane glycoprotein with three extracellular
domains: the protease-like, apical, and helical domains (29%,
25%, and 23% identical to PSMA, respectively) (23). The helical
and apical domains have no counterparts in the single- and
double-domain zinc-dependent exopeptidases (Fig. 1). TfR1
binds the hemochromatosis protein HFE and iron-loaded trans-
ferrin at overlapping binding sites (25). Both TfR1 and PSMA
are internalized into endosomes via cytoplasmic YXRF and
MXXXL motifs, respectively (26, 27). Whereas TfR1 delivers
iron-loaded transferrin and HFE to cells, PSMAmay internalize
folate or other ligands, a property that can be exploited for
targeted delivery of chemotherapeutics. Indeed, the binding of
PSMA to the monoclonal antibody J591 increases its internal-
ization rate and potential uptake of tethered ligands (28).
Here we present the 3.5-Å crystal structure of the PSMA
ectodomain (residues 44–750), which corresponds approxi-
mately to the alternatively spliced PSM protein expressed in the
cytosol (residues 60–750) (29). The structure reveals a two-fold
symmetric homodimer with overall similarity to TfR1, but
PSMA has a more compact dimer interface and an enzymatically
active protease domain. The active site of PSMA contains two
zinc atoms coordinated by histidine and glutamateaspartate
residues and a water molecule, similar to active sites in Sgap,
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AAP, PepV, PepT, and CPG2. An arginine-rich patch in PSMA
replaces the hydrophobic substrate-binding site of the amin-
opeptidases, consistent with their different substrate prefer-
ences. Substrate docking and sequence alignments suggest that
the arginine patch stabilizes the binding of a C-terminal gluta-
mate-containing substrate.
Materials and Methods
For additional experimental details, see the supporting infor-
mation, which is published on the PNAS web site.
Expression and Purification of Soluble Human PSMA. The cDNA
encoding full-length human PSMA was kindly provided by
Joseph Neale and Tomas Bzdega (Georgetown University,
Washington, DC). The extracellular portion of PSMA (residues
44–750) was subcloned into a baculovirus transfer vector
(pAcGP67A; BD Biosciences) containing a hydrophobic secre-
tion signal, Factor Xa cleavage site, and N-terminal 6x-His
affinity tag. Supernatants from High 5 cells infected with
recombinant virus were concentrated and exchanged into 50mM
Tris, pH 7.4150 mM NaCl. PSMA was purified at yields of10
milligrams of protein per liter of infected cell supernatant by
using Ni-NTA affinity (Qiagen, Chatsworth, CA) and Superdex
200 1660 (Amersham Pharmacia Biosciences) size-exclusion
chromatography. The enzymatic activity of the purified PSMA
ectodomain was within the previously reported range for cleav-
age of -NAAG by blood plasma glutamate carboxypeptidase II
(2.5–4.5 nanomoles glutamate produced per minute per milli-
gram of enzyme) (30).
Crystallization, Data Collection, and Processing. Crystals of PSMA
were obtained at 4°C in 2 days by vapor diffusion from hanging
drops containing 0.8 l of protein (at10 mgml in 20 mM Tris,
pH 7.5) and 0.8 l of reservoir solution [18% polyethylene glycol
(PEG) 33500.2 M sodium thiocyanate]. Crystals were trans-
ferred serially through increasing concentrations of glycerol and
PEG 3350 to a final concentration of 0.2 M sodium thiocyanate
28% PEG 335020% glycerol for cryopreservation. Data were
Fig. 1. Structural comparison of PSMA and related proteins. The common fold of the protease or protease-like domain consists of a central seven- to
eight-stranded mixed -sheet and 6–11 flanking -helices. Ribbon diagrams of side and top view of PSMA (A), side and top view of TfR1 (PDB ID code 1CX8) (B),
AAP (PDB ID code 1RTQ) (C), CPG2 (PDB ID code 1CG2) (D). The protease (or protease-like) domains are shown in blue, the apical domains of PSMA and TfR1 in
green, the helical domains in red, and the CPG2 dimerization domain in pink. Water molecules are red, zinc ions are orange, zinc-binding residues are yellow
sticks, and carbohydrate residues are shown in a color-coded ball-and-stick representation. Representative substrates are shown below the appropriate molecule.
R1  OH or NH2, and R2  H or CH3 for folate and methotrexate, respectively. Note: A mono--glutamated folate is shown for clarity; in poly--glutamated
folatemethotrexate, the additional glutamates (up to seven) are attached to the glutamate shown via a -peptide linkage.
Table 1. Data collection and refinement statistics for PSMA
Space group P21
Unit cell (a, b, c, ) (74.9 Å, 157.8 Å,
133.8 Å, 93.2°)
Molecules per asymmetric unit Two dimers
Resolution (outer shell) 30–3.5 Å (3.62–3.5)
Theoretical reflections in resolution range 77,001
Working set 70,431 (91.5%)
Test set 3,671 (4.8%)
Completeness (outer shell)* 99% (98.1)
Rmerge (outer shell)† 14% (43.2)
I (outer shell) 15.4 (5.9)
Rcryst‡, Rfree§ 25.2%, 28.4%
Average B factor (main chain, side chain) 66 Å2 (54, 72)
non-H atoms per asymmetric unit 22,876
Protein, Zn(II), carbohydrate, water 22,184; 8; 672; 12
rms deviation from ideality: bond, angle 0.009 Å, 1.47°
Non-Gly residues in Ramachandran plot
Most-favored 74.2%
Additionally allowed 22.9%
Generously allowed 2%
Disallowed 0.8%
*Completeness indicates number of independent reflectionstotal theoretical
number.
†Rmerge(I)  100  (I  I)I, where I is the integrated intensity of a given
reflection.
‡Rcryst(F)  Fobs  FcalcFobs, where Fobs and Fcalc are the observed and
calculated structure-factor amplitudes for the HKL reflection.
§Rfree is calculated from reflections in a test set not included in the atomic
refinement.
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collected at 100 K from two cryopreserved crystals at beamline
8.2.1 at the Advanced Light Source, Lawrence Berkeley National
Laboratory (Berkeley, CA) and beamline 11-1 at Stanford
Synchrotron and Radiation Laboratory (SSRL; Stanford, CA).
A fluorescence energy scan collected at SSRL demonstrated
that the PSMA crystals contained zinc, although no exogenous
zinc was added during purification or crystallization of the
protein. Data were collected at 1.2818 Å, the K-edge of zinc, to
aid in the location of the zinc ions. Data processing and scaling
were carried out by using the HKL package (Table 1) (31).
Crystals were indexed in spacegroup P21 with unit cell dimen-
sions a  75.8 Å, b  159.5 Å, and c  134.4 Å;   93.2° and
two PSMA dimers per asymmetric unit. Reflections were ini-
tially visible to 2.7 Å, but the crystals decayed rapidly in the
beam, and data from both crystals were combined to obtain a
complete dataset to 3.5 Å. Higher-resolution data could not be
obtained, because the P21 crystals were difficult to reproduce
due to complications from a P212121 crystal form that diffracted
to low resolution and had variable unit cell edges. Thus only 2 of
300 crystals screened provided useful diffraction data.
Structure Solution, Refinement, and Analysis. The structure was
determined by molecular replacement by using the program
AMORE (32) and a search model based on the structure of TfR1
[residues 122–197, 251–310, 328–511, and 531–750 of TfR1 from
chains C and F in TfR1 (PDB ID code 1DE4), which is
equivalent to PSMA residues 56–124, 197–269, 288–479, and
561–747]. Side chains for residues that differed between PSMA
and TfR1 were truncated to alanine. A solution was obtained for
data between 30 and 3.5 Å [Rfree 52%, Rcryst 51% after rigid
body refinement with REFMAC5 (32), in which each domain was
treated as a separate rigid body]. The model was built by using
a combination of the programs O (33) and MAIN (34) with
2FobsFcalc annealed omit maps calculated by using the CCP4
program DM and density-modified four-fold noncrystallographic
symmetry (NCS) averaged 2FobsFcalc maps. Cycles of torsional,
positional, and B group refinement (35) with a bulk solvent
correction, four-fold NCS constraints, and a zinc patch were used
to generate a final model with Rfree  28.4% and Rcryst  25.2%
for data between 30 and 3.5 Å (all reflections with F 0). An
anomalous difference Patterson map generated with CCP4 (32)
revealed two zinc ions at each active site in the PSMA ho-
modimer, both with full occupancy (as determined by refinement
using CNS), but experimental phases calculated using anomalous
scattering data from these atoms did not improve the electron
density maps. Density for a bridging ligand was modeled as a
water, but a Tris molecule, as seen in an AAP structure (36), or
another buffer component cannot be ruled out at this resolution.
Carbohydrate sites in addition to the zinc ligands aided in the
initial assignment of the amino acid register in regions where
PSMA and TfR1 shared little or no sequence identity. The final
model contains residues 56–750 of PSMA chains A–D, two zinc
ions, 12 N-acetyl glucosamine residues, and three water mole-
cules per monomer and has an overall B factor of 66 Å2.
N-terminal residues 44–55 were not observed in the density.
Results and Discussion
Overall Structure of PSMA. The structure reveals a symmetric
dimer with each polypeptide chain containing three domains
analogous to the three TfR1 domains: a protease domain
(residues 56–116 and 352–591), an apical domain (residues
117–351), and a helical domain (residues 592–750) (Fig. 1 and
Table 1). A large cavity (1,100 Å2) at the interface between the
three domains includes a binuclear zinc site (Fig. 2) and pre-
dominantly polar residues (66% of 70 residues) (supporting
information). The observation of two zinc ions and conservation
of many of the cavity-forming residues among PSMA orthologs
and homologs (Table 2) identify the cavity as the substrate-
binding site.
The protease domain of PSMA resembles the protease and
Fig. 2. A surface rendering in which the helical domain is light red, the apical
domain is light green, the protease domain is light blue, and zinc ions are
orange. The residues lining the substrate-binding cavity are highlighted in a
darker version of the color corresponding to the domain from which the
residue originates.
Table 2. Residues within or in the vicinity of the PSMA
active site
*Residues are highlighted according to their proposed roles: yellow, zinc
ligands; purple, substrate- or water-binding residues; blue, residues with
structural roles; green, residues that stabilize arginine patch.
†Counterpart residues listed in single-letter code for 10 species of PSMA (Sus
scrofa, Mus musculus, Rattus norvegicus, Danio rerio, Caenorhabditis brigg-
sae, A. thaliana, Magnaporthe grisea, Aspergillus nidulans, Neurospora
crassa, Gibberella zeae) and for NLD2, NLDL, Sgap, AAP, CPG2, pepT, pepV,
and TfR1. Mut, mutant; A, no detectable enzymatic activity; low, enzymatic
activity too low for determination of kinetic parameters; ND, not determined
or too low activity for determination of Vmax and Km.
‡Additional mutagenesis results can be found in ref. 45.
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protease-like domains of bacterial binuclear zinc exopeptidases
(Sgap, AAP, PepV, PepT, and CPG2) and TfR1, respectively
(Fig. 1), and contains 11 -helices, an eight-stranded -sheet,
and insertions (residues 485–487 and 502–510), which extend a
loop joining the sixth and seventh -strands and include a short
-helix. As in TfR1, the apical domain is inserted between
strands 1 and 2 of the protease domain -sheet. PepV, PepT, and
CPG2 (16–18) (Fig. 1D) also contain an inserted domain,
although for these proteins the insertions are between strands 6
and 7 of the central -sheet, and each serves as a dimerization
domain.
The apical domain of PSMA (also called the protease-
associated domain) consists of two -sheets, three -helices,
and one helical turn. This domain is also found in subtilases
and trafficking receptors (37). In PSMA, it forms one side of
the substrate-binding cavity. In contrast, Sgap and AAP lack
an apical domain counterpart and have more open active sites
(19, 20).
The helical domain of PSMA contains six -helices and
associated connecting regions, one of which (residues 687–704)
is involved in forming the substrate-binding cavity. Another
important function of the helical domain is in forming the dimer
interface, which involves three helices (Fig. 1A). Although
PSMA can convert between a dimeric and monomeric form in
vitro by addition of metal chelators or changes in salt concen-
tration (38), only the dimeric form of PSMA has folate hydrolase
and naaladase activity and is expressed on the surface of prostate
cells (38). The dimer interface of PSMA is large, burying a total
of 4,600 Å2, making it unlikely that an intact monomer would
dissociate from PSMAwithout at least partial unfolding, perhaps
rationalizing why PSMAmonomers are inactive (38). Consistent
with experiments demonstrating that deletion of the 15 C-
terminal residues in PSMA abolishes enzymatic activity (39), the
C-terminal residues 721–747 of PSMA form a helix at the dimer
interface, suggesting that C-terminal truncation of the ectodo-
main disrupts PSMA dimerization.
Comparison with TfR1. Although the overall structure and domain
organization of PSMA and TfR1 are similar (Fig. 1) (23, 40) (rms
deviation of 2.1 Å for 847 of 1,270 C atoms in the homodimers),
specific structural differences are relevant to their different func-
tions. First, two large insertions in the apical domain of PSMA
(residues 145–158 and 238–248) contribute to a large increase in
buried surface area between the apical and protease domains (a
total of4,170 Å2), as compared with TfR1 (2,630 Å2). There is
also a modest increase in buried surface area between the PSMA
apical and helical domains (2,830 Å2), as compared with TfR1
(2,540 Å2). These additional interdomain contacts are involved in
positioning the PSMA apical domain to form one side of the
substrate-binding cavity. In addition, insertions in the PSMAhelical
and protease domains (residues 698–703 and 543–548) narrow its
substrate-binding cavity, as compared with the analogous region of
TfR1. Finally, PSMA does not bind HFE or transferrin (data not
shown), and the residues involved in TfR1 binding to HFE or
transferrin (40–42) are nonconservatively substituted in PSMA
(supporting information).
Glycosylation of PSMA. Glycosylation of PSMA is required for
secretion of the recombinant extracellular domain, membrane
expression of full-length PSMA, and enzymatic activity (43, 44).
The PSMA ectodomain contains nine potential N-linked car-
bohydrate sites, all of which have been shown to be glycosylated
(43, 44). Seven of the glycosylation sites show carbohydrate
density in 2FobsFcalc maps (Asn-76, -121, -140, -153, -459, -476,
and -638), but none of the glycosylation sites are close enough to
the PSMA active site to directly contact a bound substrate.
Therefore, loss of enzymatic activity resulting from prevention
or removal of glycosylation (43, 44) likely results from indirect
effects, such as misfolding or inhibition of dimerization. We note
that the N-linked carbohydrates attached to Asn-638 are posi-
tioned such that they could be involved in intersubunit interac-
tions, suggesting that their removal may affect the dimerization
of PSMA, thereby resulting in the reduced enzymatic activity
associated with PSMA monomers (38).
Antibody Epitopes. The structure of PSMA clarifies the epitopes
recognized by monoclonal antibodies being studied for applica-
tions in cancer imaging and therapeutics (reviewed in ref. 4). The
epitope for the J591 antibody that is in clinical trials has been
mapped by using truncated PSMA constructs to residues 153–
347 (7). The structure reveals that this region corresponds to the
majority of the apical domain, which is distant from the mem-
brane surface (Fig. 1A) and hence generally exposed and
accessible. It was previously suggested that the epitope for J591
is near Asn-476 or the carbohydrate normally attached to this
residue, because a mutant at this site (N476A) was not detected
by J591 (43). However, the PSMA structure shows that Asn-476
is distant from the apical domain and is instead located in the
membrane-proximal region of the molecule, where it is less
accessible to antibodies.
Active Site of PSMA. The structure of PSMA also provides insight
into its catalytic mechanism and substrate specificity. Although
zinc was not added to PSMA during purification or crystalliza-
Fig. 3. The PSMA active site. (A) Stereoview of the PSMA active site. Zinc ions
are orange spheres, and a water molecule is shown as a red sphere. Zinc-
binding residues are yellow sticks, water- or substrate-binding ligands are
purple sticks, and residues with structural roles are light blue sticks. (B)
Stereoview of the PSMA model in the region of the PSMA active site super-
imposed on a 3.5-Å 2FobsFcalc annealed omit electron density map contoured
at 1 (yellow) and 4 (blue). The zinc ions and zinc-binding residues were
omitted from the model before generation of the map. Some of the extra
density corresponds to nonzinc-binding residues that were omitted from the
figure for clarity. (C) Overlay of the active sites of PSMA (yellow), aminopep-
tidase AAP (green) (PDB ID code 1RTQ), and carboxypeptidase CPG2 (blue)
(PDB ID code 1CG2) with the zinc ions as spheres and the zinc-binding residues
in ball-and-stick representation.
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tion, the crystal structure reveals two zinc atoms separated by
3.2 Å. The zinc ions are each coordinated by three endogenous
ligands: a histidine (His-553 or -377), a terminal aspartate
(Asp-453) or glutamate (Glu-425), and a bridging aspartate
(Asp-387) (Fig. 3). Additionally, a water ligand asymmetrically
bridges the zinc ions. With the exception of Asp-453, these five
endogenous zinc-binding residues are substituted in the pro-
tease-like domain of TfR1, which does not bind zinc or function
as a peptidase (23). The zinc-coordinating residues were impli-
cated in previous mutagenesis studies (45) and are conserved in
PSMA orthologs from plants to mammals, in the aminopepti-
dases Sgap, AAP, PepV, and PepT, and include a single con-
servative substitution in the bacterial carboxypeptidase CPG2
(Table 2). The active site geometries of these enzymes are similar
(Fig. 3C); e.g., the bridging ligand modeled as a water molecule
in the PSMA active site is at a similar position as a water in CPG2
and a bound Tris molecule in AAP (16–20, 36). The water
molecule in PSMA is likely to have significant hydroxide char-
acter, because a single zinc ion can lower the pKa of a water
ligand from 15.7 to 9.0 (46), and the adjacent residue Glu-424
could act as an active site base to deprotonate the bound water.
Consistent with a role in catalysis, Glu-424 is conserved in all
species of PSMA, other naaladases, AAP, Sgap, PepV, PepT,
and CPG2, and substitution of this residue leads to a reduced
Vmax and increased Km in PSMA (45) (Table 2). The analogous
residue in AAP is involved in the hydrolysis reaction and
functions as an active site acid and base (47). Another residue
that could potentially act as an active site base is Tyr-552, which
is conserved in all PSMA and PSMA-related proteins except
AAP and PepV, in which the analogous residue is an isoleucine
or a methionine, respectively (Table 2). PSMA Tyr-552 is within
3.8 Å of the water ligand, suggesting involvement in catalysis, but
its exact role remains to be elucidated.
Other residues near the zinc ligands (Asp-379, Glu-557,
Pro-388, and Asn-519) are also conserved or conservatively
substituted between PSMA orthologs and related binuclear
zinc-dependent exopeptidases (Table 2). Substitutions of the
strictly conserved Asp-379, which is within hydrogen-bonding
distance of the zinc ligand His-377, abolish detectable enzymatic
activity (Table 2). Glu-557 is within hydrogen-bonding distance
of the backbone nitrogen of Asp-387 and is either a glutamate
or aspartate in all PSMA orthologs and related binuclear
zinc-dependent exopeptidases. Pro-388, which was modeled as a
cis-peptide in the PSMA structure, occupies a position at which
residues with a cis-peptide conformation are found in the
mononuclear (48, 49) and binuclear (16–19, 36) zinc-dependent
exopeptidases. This residue is broadly conserved across different
species of PSMA, and alanine substitution results in an increased
Km (Table 2). The substitution of Asn-519, which is within 3.8 Å
of the active site water molecule, affects enzymatic activity (45),
and this residue (or its serine or threonine counterpart in
nonmammalian PSMAs and other related peptidases) could be
involved in hydrogen bonding to the C or N terminus of the
substrate (Table 2).
Substrate-Binding Cavity of PSMA. The substrate-binding cavity
contains a patch of three arginines (Arg-463, -534, and -536),
which are clustered within 4.5 Å of each other and located 6–12
Å from the nearest zinc ion. The arginines in the patch are
stabilized by interactions with Glu-457, Asp-465, and Ser-454.
The arginine patch is conserved in mammalian and zebrafish
PSMA (Table 2) and may be involved in correctly orienting
substrates for catalysis by interacting with the negatively charged
C-terminal glutamate residue. The positively charged character
of the cavity is in contrast to the hydrophobic substrate-binding
cavities found in aminopeptidases, which accommodate sub-
strates with apolar residues (50). Nonconservative substitutions
of PSMA residues Arg-463 and -536 result in increased Km
values, and mutagenesis of Ser-454 leads to a decrease in Vmax
(45) (Table 2). Similarly, CPG2, which cleaves folic acid and
methotrexate (51), also includes three arginines near its active
site (CPG2 residues Arg-262, -288, and -324, which are 8–19 Å
away from the nearest zinc ion) (16). A mutant at the nearest of
these arginines (R324A) showed reduced cleavage of metho-
trexate (16). In PSMA, a fourth arginine, Arg-210 from the
apical domain, which is 100% conserved in all PSMA orthologs
and NLD2 and NLDL, is situated on the opposite side of the
cavity and may also be involved in substrate binding.
An arginine-rich substrate-binding cavity is also observed in
carboxypeptidase A (48), although this enzyme is not specific for
C-terminal glutamate-containing substrates. In this case, the argi-
nines are not clustered but rather are more linearly arranged with
a distance of 9.0 Å between the two furthest arginines. The
arginine that is closest to the active site zinc (4 Å) is proposed to
stabilize the tetrahedral intermediate (52). The two other arginines
are both 7 Å from the zinc ion but 9 Å from each other. Thus,
although an arginine-lined substrate-binding cavity is a general
feature of zinc carboxypeptidases that facilitates interactions with
carboxyl groups, the clustering of the four arginines in the substrate-
binding cavity of PSMA could provide additional specificity for
substrates with C-terminal glutamate residues.
Conservation of all four arginine residues correlates with the
ability of PSMA and NLD2 to cleave -NAAG (2), consistent
with the proposed role of these arginine residues in binding
substrates containing C-terminal glutamates. NLDL and Arabi-
dopsis thaliana PSMA (AMP1) (53) do not cleave -NAAG, and
they lack two or three of the four arginines, respectively (Table
2). In NLDL, only Arg-210 and -463 are present, and in AMP1,
only Arg-210 is present. Threading of the sequences of NLDL
and AMP1 onto the structure of human PSMA suggests that the
NLDL and AMP1 substrate-binding cavities do not contain
compensating arginine residues (data not shown) but rather have
hydrophobic substrate-binding cavities, suggesting interactions
with apolar substrates. Although the substrate for AMP1 has not
been identified, plants with AMP1 mutations show changes in
apical meristem size, suggesting the importance of this PSMA
Fig. 4. A mechanistic scheme for-NAAG (glutamate is red, and NAA is blue)
binding and cleavage by PSMA (black). The zinc-binding PSMA residues are
assumed to remain bound during the reaction mechanism and are omitted in
the substrate-binding and cleavage steps for clarity. The C-terminal carboxyl
group binds the zinc ions in a bridging fashion, and there are electrostatic
interactions between the glutamate side chain and the arginine patch and the
aspartate side chain and Arg-210. The zinc-bound water molecule is poised to
attack the peptide bond of the bound substrate, leading to a tetrahedral
intermediate, bond cleavage, and product dissociation. An analogous mech-
anism would be expected for the cleavage of -NAAG by NLD2 (2).
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ortholog in plant development and a potential role for its
substrate as a signaling compound (53).
Mechanistic Implications. Taken together with prior crystallo-
graphic and mechanistic studies of members of the zinc-
dependent exopeptidase superfamily (16–19, 36, 47–49, 54, 55),
we can use the structure and substrate docking results (support-
ing information) to propose a catalytic mechanism for the
cleavage of -NAAG by PSMA (Fig. 4) that is consistent with
mutagenesis studies. In this mechanism, -NAAG binds such
that the glutamate side chain forms electrostatic interactions
with the arginine patch of PSMA, and the oxygen from the
carbonyl to be attacked and the C terminus bind to the zinc ions.
The remainder of the substrate (e.g., N-acetyl-aspartate in
-NAAG) is accommodated by the substrate-binding cavity with
specific interactions with Arg-210. Larger substrates [e.g., poly-
-glutamated folates with up to four -linked glutamates (9)]
require some structural rearrangements to avoid steric clashes
with the pocket and could have an alternate mode of binding.
Nevertheless, the proposed reaction mechanism is the same:
binding of one water molecule to the zinc ions and deprotonation
by Glu-424 to activate the water molecule for nucleophilic attack
of the peptide bond of the bound substrate, leading to a
tetrahedral intermediate, bond cleavage, and product dissocia-
tion. This mechanism is consistent with catalysis by other
members of the zinc-dependent exopeptidase superfamily, in
which each active site includes one water molecule that is
activated for nucleophilic attack of the peptide bond through
deprotonation by a nearby carboxylate (Glu-424 for PSMA)
(16–19, 36, 47–49, 54). The active site architecture of PSMA and
its implications for substrate binding and catalysis provide
insight into the function of this important enzyme and a rationale
for designing reagents for detection and treatment of cancer
andor neurological disorders.
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